Adi E. Mehta, MD

Michael B. Davidson, DO
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic

Adi E. Mehta, MD
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic

Elias S. Siraj, MD
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic

Address: Elias S. Siraj, MD, Department of Endocrinology, Diabetes, and Metabolism, A53, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail siraje@ccf.org

Michael B. Davidson, DO
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic

Adi E. Mehta, MD
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic

Elias S. Siraj, MD
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic

Address: Elias S. Siraj, MD, Department of Endocrinology, Diabetes, and Metabolism, A53, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail siraje@ccf.org

Michael B. Davidson, DO
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic

Adi E. Mehta, MD
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic

Elias S. Siraj, MD
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic

Address: Elias S. Siraj, MD, Department of Endocrinology, Diabetes, and Metabolism, A53, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail siraje@ccf.org

Theresa L. Marx, MD
Department of Endocrinology, The Cleveland Clinic

Adi E. Mehta, MD
Department of Endocrinology, The Cleveland Clinic

Address: Adi E. Mehta, MD, Department of Endocrinology, A53, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Mehta has indicated that he is on the speaker’s bureaus of the Bristol-Myers, GlaxoSmithKline, Knoll, Eli Lilly, Pfizer, and Takeda corportions.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Theresa L. Marx, MD
Department of Endocrinology, The Cleveland Clinic

Adi E. Mehta, MD
Department of Endocrinology, The Cleveland Clinic

Address: Adi E. Mehta, MD, Department of Endocrinology, A53, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Mehta has indicated that he is on the speaker’s bureaus of the Bristol-Myers, GlaxoSmithKline, Knoll, Eli Lilly, Pfizer, and Takeda corportions.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Theresa L. Marx, MD
Department of Endocrinology, The Cleveland Clinic

Adi E. Mehta, MD
Department of Endocrinology, The Cleveland Clinic

Address: Adi E. Mehta, MD, Department of Endocrinology, A53, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Mehta has indicated that he is on the speaker’s bureaus of the Bristol-Myers, GlaxoSmithKline, Knoll, Eli Lilly, Pfizer, and Takeda corportions.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.